argenx SE
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
13 mar 2015 - 07:25
Statutory name
argenx SE
Title
arGEN-X to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference
Comments
Breda, the Netherlands / Ghent, Belgium, 13 March 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Scientific Officer, Prof. Hans de Haard, Ph.D., will present a corporate update at the 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference in New York City (NY, USA) on Friday, 20 March 2015 at 9:30am ET.
Date last update: 06 April 2026